Participants recruited that pass the inclusion and exclusion criteria

Malaria

Falciparum Malaria

Vivax Malaria

Three days according to body weight (Days 0, 1 and 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines).

Arthemeter-lumefantrine

Chloroquine according to body weight as a total dose of 25mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Primaquine will be withheld for 28 days. It will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.

Chloroquine

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria and Chloroquine for the Treatment of Plasmodium Vivax in the Philippines

Development of danger signs or severe malaria on day 1, day 2 or day 3 in the presence of parasitaemia; Parasitaemia on day 2 higher than day 0 count irrespective of axillary temperature; Parasitaemia on day 3 with axillary temperature ≥37.5 degree celsius; Parasitaemia on day 3 ≥25% of count on day 0.

Development of danger signs or severe malaria on any day from day 4 to day 28 in the presence of parasitaemia, without previously meeting any of the criteria of Early Treatment Failure; Presence of parasitaemia and axillary temperature ≥37.5 degree celsius (or history of fever in low/moderate transmission areas) on any day from day 4 to day 28, without previously meeting any of the criteria of Early Treatment Failure.

Absence of parasitaemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure.

artemether/edema

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu